Organon & Co
OGN
查看详细走势图
7.185USD
+0.095+1.34%
收盘 12/26, 16:00（美东）报价延迟15分钟
1.87B总市值
3.72市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+1.34%
5天
+5.20%
1月
-7.17%
6月
-28.01%
今年开始到现在
-51.84%
1年
-51.94%
查看详细走势图
TradingKey Organon & Co股票评分
单位: USD 更新时间: 2025-12-26操作建议
Organon & Co当前公司基本面数据相对稳定，增长潜力很大。当前估值合理，在药品行业排名84/158位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价9.36。中期看，股价处于下降通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Organon & Co评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
9
位分析师
持有
评级
9.357
目标均价
+28.36%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Organon & Co亮点
亮点风险
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
高分红
公司属于高分红公司，最新股息支付率34.38%
估值低估
公司最新PE估值3.71，处于3年历史低位
机构减仓
最新机构持股219.88M股，环比减少14.54%
加拿大丰业银行分红基金持仓
明星投资者加拿大丰业银行分红基金持仓，最新持仓市值44.51K
Organon & Co新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Organon & Co简介
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
公司代码OGN
公司Organon & Co
CEOMorrissey (Joseph T)
网址https://www.organon.com/
常见问题
Organon & Co(OGN)的当前股价是多少？
Organon & Co(OGN)的当前股价是 7.185。
Organon & Co的股票代码是什么？
Organon & Co的股票代码是OGN。
Organon & Co股票的52周最高点是多少？
Organon & Co股票的52周最高点是17.230。
Organon & Co股票的52周最低点是多少？
Organon & Co股票的52周最低点是6.180。
Organon & Co的市值是多少？
Organon & Co的市值是1.87B。
Organon & Co的净利润是多少？
Organon & Co的净利润为864.00M。
现在Organon & Co(OGN)的股票是买入、持有还是卖出？
根据分析师评级，Organon & Co(OGN)的总体评级为持有，目标价格为9.357。
Organon & Co(OGN)股票的每股收益（EPS TTM）是多少
Organon & Co(OGN)股票的每股收益（EPS TTM）是1.934。
相关品种
